Nature Communications (Oct 2022)
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma
Abstract
Responses to immune checkpoint blockade (ICB) in patients with glioblastoma are limited. Here the authors show that Calmodulin-Dependent Kinase Kinase 2 (CaMKK2) is expressed in tumor associated macrophages and neurons and is associated with resistance to ICB in preclinical models of glioblastoma.